TCIM
CASI

TIAA CREF Investment Management’s CASI Pharmaceuticals CASI Stock Holding History

TIAA CREF Investment Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$280K Sell
9,760
-44
-0.4% -$1.53K ﹤0.01% 2797
2018
Q4 		$394K Sell
9,804
-173
-2% -$6.55K ﹤0.01% 2668
2018
Q3 		$466K Sell
9,977
-1,110
-10% -$77.5K ﹤0.01% 2744
2018
Q2 		$912K Buy
+11,087
New +$748K ﹤0.01% 2532

Other funds holding CASI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TIAA CREF Investment Management's CASI Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its CASI Pharmaceuticals (CASI) stake by 0.45% in Q1 2019, selling an estimated $1.53K and leaving 9,760 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #2797.

TIAA CREF Investment Management first reported a position in CASI in Q2 2018 and has held it in 4 quarters since. The position peaked at $912K in Q2 2018. 52 funds tracked by Wall St. Rank hold CASI as of Q1 2019.

  • TIAA CREF Investment Management held 9,760 shares of CASI Pharmaceuticals worth $280K as of Q1 2019.
  • TIAA CREF Investment Management sold 44 CASI Pharmaceuticals shares in Q1 2019, an estimated $1.53K.
  • CASI Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2797 holding.
  • TIAA CREF Investment Management first reported a position in CASI Pharmaceuticals in Q2 2018 and has held it in 4 quarters since.
  • TIAA CREF Investment Management's CASI Pharmaceuticals position peaked at $912K in Q2 2018.
  • 52 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.